At a Glance
- Company: CellCentric
- Location: Cambridge, UK/Boston, US
- Funding: $220M oversubscribed Series D
- Lead investor: Venrock Healthcare Capital Partners
- Focus: inobrodib (p300/CBP inhibitor)
What happened?
CellCentric announced the closing of a $220 million oversubscribed Series D financing on 6 May 2026 to advance pivotal trials of inobrodib for multiple myeloma. Led by Venrock, it included Fidelity, Sofinnova, HBM and existing investors like RA Capital and Pfizer.
Why does it matter?
Inobrodib is an oral first-in-class p300/CBP inhibitor targeting epigenetic drivers in post-bispecific/refractory myeloma. Phase 2 data showed 75% ORR; funds support registration-enabling MINO1/MINO2 trials and combos/maintenance studies, positioning it for accelerated approval.
Who’s behind it?
CEO Will West leads; board adds Venrock’s Bob Tepper. Funds extend runway to 2029, supporting IPO path.
How was it achieved?
Proceeds fund MINO1 (heavily pretreated RRMM), MINO2 (post-BCMA/bispecific), bispecific combos and maintenance. Builds on Phase 2a InoPd data (75% ORR).
What’s next?
Pivotal enrolment; Phase 3 mid-2026; FDA Fast Track/Orphan status. Potential transformative post-bispecific option.
What are people saying?
Will West, CEO: “Investors recognise inobrodib’s potential… critical gap after bispecifics.” Bob Tepper, Venrock: “Transformative for myeloma treatment.”